Abstract:Background: A ketogenic regimen is high in fat (90%kCal) and low in carbohydrates (5% kCal), resulting in a state of ketosis[2]. Prior studies suggest that a ketogenic diet shifts carbon utilization in cancer cells from one that is predominantly glycolytic, towards the tricarboxylic acid cycle (TCA) in the mitochondria[3]. The net effect on cancer growth remains uncertain, but the majority of studies in the literature favor an anti-cancer signal. We hypothesize that molecular and biochemical insights into how pancreatic cancer cells adapt to a ketogenic diet will uncover metabolic vulnerabilities and nominate rationally designed therapeutic strategies to effectively partner with the diet. Methods: A ketogenic diet was administered to mice, along with a normal diet in control mice. Pancreatic cancer xenografts were monitored for growth and harvested for biochemical analyses. Tumors were analyzed for metabolites by LC/GC-MS and for oxidative stress by measuring the levels of NADP+/NADPH, NAD+/NADH and Lipid Peroxidation assay. Enzyme expression was assessed by Western blot. For in vitro studies, mitochondrial function was analyzed by the Seahorse FX Analyzer and cell growth was measured by PicoGreen DNA quantitation. Result: A ketogenic diet slowed pancreatic cancer growth in multiple in vivo models, including MIA-PaCa2, KPC and patient derived xenografts. TCA metabolites were broadly increased in xenografts exposed to a ketogenic diet. In these mouse tumors, metabolic enzymes associated with the TCA cycle were markedly upregulated, pointing to an effect on gene expression. Specifically, the expression of BDH1 (a ketolytic enzyme allowing ketone body utilization in cancer cells), IDH1 (cytosolic and supports antioxidant defense and mitochondria through NADPH and α-ketoglutarate) and IDH2 (a homolog of IDH1 in the mitochondria) were all increased. In contrast, the glycolytic enzyme, G3P, was reduced. 3). additionally, a ketogenic diet induced oxidative stress in pancreatic cancer in vivo. Based on the adaptations observed in pancreatic cancer, we combined a ketogenic diet with an inhibitor of IDH1 to thwart antioxidant defense and impair mitochondrial function. The combination resulted in markedly reduced tumor proliferation, compared to either treatment alone. In vitro studies revealed that low glucose and fatty acids are likely the major drivers of reduced pancreatic cancer cell proliferation with a ketogenic diet, while exogenous ketone bodies are utilized for energy by mitochondria under glucose withdrawal and generally have a pro-tumor effect. Conclusion: A ketogenic diet has a strong anti-tumor effect in multiple pancreatic cancer mouse models, and the effect is likely a result of the low glucose and increased fatty acid load associated with the diet. Metabolic adaptation towards an OXPHOS phenotype renders pancreatic cancer especially susceptible to antioxidant and mitochondrial inhibitors. Citation Format: Mehrdad Zarei, Soubhi Tahhan, Peter Gallagher, William Beegan, Alexander Loftus, Kevin Lebo, Shihong Lei, Helen Cheng, Anusha Mudigonda, Jonathan Hue, Hallie Graor, Omid Hajihassani, Jordan Winter, Karen Ji, Sydney Alibeckoff. Determining the anti-cancer properties of a ketogenic diet against pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr B050.

Ketogenic diet reshapes cancer metabolism through lysine β-hydroxybutyrylation

Pan-Cancer Analysis of Glycolytic and Ketone Bodies Metabolic Genes: Implications for Response to Ketogenic Dietary Therapy

Abstract 442: Exploring targetable pathways: Unveiling changes in tumor physiology through dietary modification by a ketogenic diet

Molecular Mechanisms for Ketone Body Metabolism, Signaling Functions, and Therapeutic Potential in Cancer

Metabolic Regulation of Gene Expression by Histone Lysine β‐hydroxybutyrylation

Ketogenic β‐hydroxybutyrate regulates β‐hydroxybutyrylation of TCA cycle‐associated enzymes and attenuates disease‐associated pathologies in Alzheimer's mice

In Vitro Simulated Ketogenic Diet Inhibits the Proliferation and Migration of Liver Cancer Cells by Reducing Insulin Production and Down-regulating FOXC2 Expression

Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma

The Ketogenic Diet Alters the Hypoxic Response and Affects Expression of Proteins Associated with Angiogenesis, Invasive Potential and Vascular Permeability in a Mouse Glioma Model

Posttranslational regulation of liver kinase B1 in human cancer

Metabolism‐Based Molecular Subtyping Endows Effective Ketogenic Therapy in p53‐Mutant Colon Cancer

An unexpected role for the ketogenic diet in triggering tumor metastasis by modulating BACH1-mediated transcription

Ketogenic Diets and Hepatocellular Carcinoma

Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade

Metabolic alterations and cellular responses to β-Hydroxybutyrate treatment in breast cancer cells

Abstract C052: Ketogenic diet enhanced nutrient metabolic pathways but did not inhibit tumor growth in an obesity-associated PDAC mouse model

The proteomic effects of ketone bodies: implications for proteostasis and brain proteinopathies

Abstract 291: A ketogenic diet rewires pancreatic cancer metabolism towards an actionable metabolic

Anti-Tumor Effects of Ketogenic Diets in Mice: A Meta-Analysis

The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer

Abstract B050: Determining the anti-cancer properties of a ketogenic diet against pancreatic cancer